Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available ...

CASGEVY is expecting more approvals from various global regulatory bodies, potentially increasing the total addressable patients. The management team is attempting to make CASGEVY more accessible ...

The invention has made it onto TIME’s 2025 Best Inventions list, in the food and drink category, and would be the first new ...

SAN DIEGO--(BUSINESS WIRE)--CRISPR QC, a biotechnology start-up based in San Diego, is pleased to announce a major stride in its ongoing Series A funding round. Known for their CRISPR Analytics ...

CRISPR Therapeutics recently presented new preclinical data at the ESGCT 2025 Annual Congress showing its investigational CTX460, using the SyNTase gene editing platform, achieved greater than 90% ...

Now, it’s worth noting Stock Advisor's total average return is 1,064% — a market-crushing outperformance compared to 191% for ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the time. Every now and then, though, the right opportunity comes along.

The rise of CRISPR-based therapies has reshaped the biopharmaceutical landscape, offering unprecedented opportunities for ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...